Results 241 to 250 of about 470,839 (363)

Angiotensin‑converting enzyme 2 expression in human tumors: Implications for prognosis and therapy (Review). [PDF]

Oncol Rep
Rizopoulos T, Assimakopoulou M.
europepmc   +1 more source

Tripeptidylcarboxypeptidase activity of angiotensin I converting enzyme in human serum. [PDF]

, 1983
Hugo Neels, Jin‐ichi Inokuchi, Akio NAGAMATSU, M. van Sande, Simon Scharpé   +4 more
openalex   +1 more source

Early in‐hospital treatment of acute heart failure. Part 2 of the international expert opinion series on AHF management

ESC Heart Failure, EarlyView.
This state‐of‐the‐art review outlines a practical, evidence‐based framework for early acute heart failure management to address critical gaps in current guidance and improve early treatment outcomes. Key components include early identification of co‐existing conditions, bedside haemodynamic profiling, a structured diagnostic approach incorporating both
Anika S. Naidu, Andrew P. Ambrosy, Gad Cotter, Edimar A. Bocchi, Javed Butler, Ovidiu Chioncel, Beth Davison, Anastase Dzudie, Yonathan Freund, Marat Fudim, Sivadasanpillai Harikrishnan, Ivna G. Cunha, Alexandre Mebazaa, Robert J. Mentz, Òscar Miró, Siti E. Nauli, Mateo Pagnesi, Naoki Sato, Gianluigi Savarese, Karen Sliwa‐Hahnle, Yuhui Zhang, Jingmin Zhou, Jan Biegus   +22 more
wiley   +1 more source

Discovery of novel angiotensin-converting enzyme inhibitory peptides by <i>in silico</i> and <i>in vitro</i> studies. [PDF]

RSC Adv
Jiao F, Yang J, Wang F, Peng S, Zhou B.
europepmc   +1 more source

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MI

ESC Heart Failure, EarlyView.
Impact of empagliflozin in patients with and without T2D or CKD in the EMPACT‐MI trial. Baseline characteristics, HF outcomes and subgroup analysis of efficacy endpoints are shown. # Hazard ratios estimated via Cox proportional hazard model (unless indicated otherwise). ^ Rate ratios via negative binomial regression.
Francesco Fioretti, Javed Butler, Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Johann Bauersachs, Antoni Bayes‐Genis, Shaun G. Goodman, Tomasz Gasior, James L. Januzzi, Renato D. Lopes, Piotr Ponikowski, Xavier Rossello, Morten Schou, Peter van der Meer, Dragos Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez, Stefan D. Anker   +23 more
wiley   +1 more source

Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and the Risk of Acute Pancreatitis: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Alves C, Costa B, Penedones A, Mendes D, Batel Marques F.   +4 more
europepmc   +1 more source

Role of Bradykinin in Anaphylactoid Reactions during Hemodialysis with AN69 Dialyzers [PDF]

, 1993
Barkhausen, Regina, Fink, Edwin, Heidland, August, Kulzer, Peter, Schaefer, Liliana, Schaefer, Roland M.   +5 more
core   +1 more source

Angiotensin Converting Enzyme 2: A Double-Edged Sword.

Circulation, 2020
Kaiming Wang, Mahmoud Gheblawi, G. Oudit
semanticscholar   +1 more source

A prospective analysis of management and outcomes of worsening heart failure in the outpatient setting

ESC Heart Failure, EarlyView.
Abstract Aims There is growing recognition of the burden and prognostic significance of WHF treated in the outpatient setting. However, there is currently a lack of prospective real‐world data in this area of HF care. This study aims to analyse the natural history of outpatient WHF.
Joseph McCambridge, Fiyinfoluwa Fabamwo, Shadia Taha, Dermot McCaffrey, Matthew Barrett, Ciara Mahon, Kenneth McDonald   +6 more
wiley   +1 more source

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

, 2000
S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais   +5 more
semanticscholar   +1 more source